ICA1L

ICA1L is a BAR-domain protein that functions in vesicle trafficking during male germ cell development through a physical complex with PICK1 (PMID:26306493). In testes, ICA1L is the major binding partner of PICK1 and stabilizes its protein levels; loss of ICA1L collapses testicular PICK1 expression and disrupts acrosome, nuclear, and mitochondrial sheath formation during spermiogenesis, producing a globozoospermia-like phenotype and reduced male fertility, with combined ICA69/ICA1L loss causing complete sterility (PMID:26306493). Independently of this physiological role, ICA1L is recurrently captured in oncogenic SRF::ICA1L gene fusions found in cellular myoid and pericytic soft tissue tumors, which express smooth muscle markers (PMID:31478943). The fusion protein localizes to the nucleus, dimerizes through the SRF MADS box, and acts as a constitutively active transcription factor that binds SRF target promoters and drives a muscle-gene transcriptional program through a cryptic transactivation domain contributed by ICA1L, promoting mesenchymal cell growth.

1. 2015 High

   Establishing ICA1L's physiological function: it was unknown whether ICA1L had a defined cellular role, and this work showed it forms a complex with PICK1 in testes and is required for sperm formation, defining a role in spermiogenesis-associated vesicle trafficking.

   Evidence Co-IP/pulldown for PICK1 binding plus CRISPR-Cas9 knockout mice with histological and motility analysis of sperm

   PMID:26306493

   Open questions at the time

   • Molecular mechanism by which the ICA1L-PICK1 complex directs acrosome and membrane trafficking is not resolved
   • Whether ICA1L functions outside testes is not addressed
   • Direct biochemical role of the BAR domain in membrane curvature/vesicle formation not tested
2. 2020 Medium

   Linking ICA1L to oncogenesis: it was unknown that ICA1L participated in tumor-driving rearrangements, and targeted sequencing revealed recurrent SRF-ICA1L fusions in cellular myoid tumors, defining a candidate driver event.

   Evidence Targeted RNA sequencing and FISH on myoid soft tissue tumors with smooth muscle marker IHC

   PMID:31478943

   Open questions at the time

   • No functional reconstitution to prove the fusion is oncogenic
   • Single institution, small sample number
   • Mechanism of transcriptional dysregulation not addressed
3. 2021 Low

   Testing recurrence of the fusion: the SRF-ICA1L fusion was detected in myofibroma alongside other SRF fusions, supporting that this is a recurrent event across pericytic/myoid tumor types.

   Evidence Deep RNA sequencing of tumor samples with immunofluorescence validation

   PMID:33830670

   Open questions at the time

   • Single detection within a study focused on a different fusion; no functional follow-up of ICA1L fusion
   • No mechanistic characterization
   • Frequency across tumor cohorts not established
4. 2025 Medium

   Defining the oncogenic mechanism: it was unknown how SRF::ICA1L drives tumorigenesis, and functional dissection showed the fusion is a nuclear, MADS-box-dimerizing, constitutively active transcription factor that uses a cryptic ICA1L-encoded transactivation domain to drive muscle-gene programs.

   Evidence Nuclear fractionation/imaging, dimerization assays, promoter-binding and reporter assays, mutagenesis to map the TAD, and mesenchymal stem cell overexpression with transcriptomics (preprint)

   Open questions at the time

   • Not yet peer-reviewed
   • In vivo tumorigenesis of the fusion not demonstrated
   • Relationship between the cryptic TAD and ICA1L's normal BAR-domain function is unexplored
5. 2025 Low

   Expanding the clinical spectrum: SRF fusions including ICA1L were cataloged in pediatric-type myoid neoplasms showing smooth muscle differentiation, broadening the tumor contexts in which the fusion occurs.

   Evidence RNA sequencing/FISH molecular analysis of 78 pediatric soft tissue tumors

   PMID:39864664

   Open questions at the time

   • Catalog-type detection with no ICA1L-specific functional experiment
   • Does not establish causal contribution of the fusion to phenotype
   • Mechanistic distinction between SRF fusion partners not addressed

• How ICA1L's normal BAR-domain trafficking function relates to the transcriptional activity of its cryptic TAD in the fusion context, and the direct biochemical role of the ICA1L-PICK1 complex in membrane dynamics, remain unresolved.
• No structural model of the ICA1L BAR domain or its membrane interactions
• No mechanistic account of how a trafficking protein contributes a transactivation domain
• In vivo oncogenicity of SRF::ICA1L not demonstrated